Extended Data Fig. 1: Headgroup-modified lipids for IL-12 conjugation.
From: IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer
a, Chemical structure of headgroup-modified lipids with either chelated nickel or N-aryl maleimide. N-aryl maleimide was employed to prevent potential thiosuccinimide retro-Michael addition and subsequent thiol-exchange, as this headgroup favors thiosuccinimide hydrolysis into stable succinamic acid thioethers. b, IL-12 crystal structure derived from PDB 1F45 showing C-terminus used to engineered terminal poly-histidine (polyHis) tag and terminal cysteine. c, Reaction pathway for irreversible maleimide-based conjugation with thiols.
